Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
Read more at The Wall Street Journal
-
Novartis Lifts Guidance Again After Key Drugs Help Results
Business - The Wall Street Journal - October 29 -
Why gold is a key asset in recession-proof portfolios
Top stories - CBS News - October 23 -
ING Lifts Outlook After Profit Beat
Business - The Wall Street Journal - October 31 -
Siemens Energy Lifts Outlook on Power Demand Boom
Business - The Wall Street Journal - November 13 -
Deutsche Telekom Lifts Outlook After Profit Beat
Business - The Wall Street Journal - November 14 -
Aegon Lifts Outlook, Launches $158 Million Buyback
Business - The Wall Street Journal - 6 days ago -
Unilever Backs Outlook After Sales Growth
Business - The Wall Street Journal - October 24 -
Mattel Lowers Sales Outlook After Barbie Sales Weigh
Business - The Wall Street Journal - October 23 -
Eni Cuts Profit Outlook on Weak Prices, Lifts Buybacks
Business - The Wall Street Journal - October 25
More from The Wall Street Journal
-
Boohoo Changes Chairman as Frasers Calls For Removal
Business - The Wall Street Journal - 3 hours ago -
Resolute Mining Says CEO, Employees Released From Detention in Mali
Business - The Wall Street Journal - 4 hours ago -
JD Sports Expects Profit at Lower End of Guidance
Business - The Wall Street Journal - 4 hours ago -
Julius Baer Assets Rise as Inflows Accelerate
Business - The Wall Street Journal - 5 hours ago -
Zurich Insurance Targets Higher Earnings Growth
Business - The Wall Street Journal - 5 hours ago
